Regeneron Pharmaceuticals Inc. won FDA approval for its Sanofi SA-partnered biologic, Dupixent (dupilumab), as a treatment for adults with moderate to severe atopic dermatitis (AD) who are either not helped by topical drugs or for whom those therapies aren’t advised, a group estimated to encompass about 300,000 patients in the U.S.